On Monday, Shares of Time Warner Inc (NYSE:TWX), remain flat and closed at $86.80 in the last trading session. The last trading range of the stock ranges between $86.47 and $87.14. Time Warner Inc. (TWX) recently declared that Warner Bros. Chairman and Chief Executive Officer Kevin Tsujihara will take part in the Credit Suisse 20th Annual Technology, Media & Telecom Conference on Tuesday, November 29, 2016, in Scottsdale, AZ.
Mr. Tsujihara’s remarks are expected to begin at about 12:30 p.m. MT (2:30 p.m. ET). An audio webcast will be available online.
Amicus Therapeutics, Inc. (NASDAQ:FOLD), jumped 1.09% and closed at $9.30 in the last trading session. The last trading range of the stock ranges between $8.94 and $9.35. The company’s Market capitalization is $1.37 Billion with the total Outstanding Shares of 142.33 million. Amicus Therapeutics (FOLD), a global biotechnology company at the forefront of rare and orphan diseases, recently declared that data from the pivotal Phase 3 Study 012 (ATTRACT) evaluating the efficacy and safety of the oral pharmacological chaperone migalastat contrast with Enzyme Replacement Therapy (ERT) in individuals with Fabry disease were published online in the Journal of Medical Genetics1.
“We are honored that the Journal of Medical Genetics has published our pivotal Phase 3 ATTRACT study in patients with Fabry disease who were switched from ERT to migalastat,” said Jay Barth, MD, Chief Medical Officer of Amicus Therapeutics, Inc. “We believe that this 18-month, randomized, active-controlled study generated a strong clinical data set for our precision medicine migalastat. This Phase 3 study, together with our Phase 3 Study 011 in Fabry patients who were naïve to treatment, supported the European Commission’s full approval for migalastat in the European Union as a first line therapy for Fabry disease in patients 16 years and older who have an amfacilitate genetic mutation. This publication is a major accomplishment, and I would like to thank the physicians who were investigators in this study, in addition to the patients and families who take partd in the study.”